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Increased susceptibility to the protease inhibitors saquinavir and amprenavir has been observed in human
immunodeficiency virus type 1 (HIV-1) with specific mutations in protease (V82T and N88S). Increased sus-
ceptibility to ritonavir has also been described in some viruses from antiretroviral agent-naı¨ve patients with
primary HIV-1 infection in association with combinations of amino acid changes at polymorphic sites in the
protease. Many of the viruses displaying increased susceptibility to protease inhibitors also had low replication
capacity. In this retrospective study, we analyze the drug susceptibility phenotype and the replication capacity
of virus isolates obtained at the peaks of viremia during five consecutive structured treatment interruptions in
12 chronically HIV-1-infected patients. Ten out of 12 patients had at least one sample with protease inhibitor
hypersusceptibility (change <0.4-fold) to one or more protease inhibitor. Hypersusceptibility to different pro-
tease inhibitors was observed at variable frequency, ranging from 38% to amprenavir to 11% to nelfinavir.
Pairwise comparisons between susceptibilities for the protease inhibitors showed a consistent correlation among
all pairs. There was also a significant relationship between susceptibility to protease inhibitors and replication
capacity in all patients. Replication capacity remained stable over the course of repetitive cycles of structured
treatment interruptions. We could find no association between in vitro replication capacity and in vivo plasma
viral load doubling time and CD4 and CD8 T-cell counts at each treatment interruption. Several mutations
were associated with hypersusceptibility to each protease inhibitor in a univariate analysis. This study extends
the association between hypersusceptibility to protease inhibitors and low replication capacity to virus isolated
from chronically infected patients and highlights the complexity of determining the genetic basis of this phe-
nomenon. The potential clinical relevance of protease inhibitor hypersusceptibility and low replication capacity
to virologic response to protease inhibitor-based therapies deserves to be investigated further.
Antiretroviral treatment of human immunodeficiency virus
type 1 (HIV-1) infection does not successfully suppress HIV
replication in all patients (5, 14, 16, 20). Continued viral rep-
lication in the presence of selective drug pressure leads to anti-
retroviral agent resistance, hindering the efficacy of subsequent
treatment. Both phenotypic and genotypic assays are available
to monitor drug resistance, and their results have been incor-
porated into the management of HIV-1-infected individuals in
the last few years (13, 27). Different prospective studies sup-
port at least short-term clinical utility of HIV resistance testing
in treatment-experienced patients (2–4, 7, 33).
The routine use of highly reproducible phenotypic assays
(24) revealed that many clinical HIV-1 isolates exhibited sig-
nificant hypersusceptibility (defined as a change in the 50%
inhibitory concentration versus the reference of 0.4-fold) to
the non-nucleoside reverse transcriptase inhibitor class (12, 31,
34). This phenomenon is associated with previous nucleo-
side analogue treatment and with an increase in the efficacy
of salvage antiretroviral regimens including non-nucleoside
reverse transcriptase inhibitors (12, 31, 32, 34). In chronically
infected antiretroviral-experienced patients, amprenavir hy-
persusceptibility is associated with the N88S mutation in pro-
tease, which is not seen in drug-naı¨ve patients (26, 35). Several
mutations in protease have been correlated with increased
susceptibility to each protease inhibitor in wild-type viruses
(23). A more recent study also showed that ritonavir hypersus-
ceptibility in HIV from recently infected, untreated patients is
not associated with a particular single mutation but with com-
binations of amino acids at polymorphic sites and that the
same genotypes which confer hypersusceptibility to protease
inhibitors also confer low in vitro replication capacity (15).
The present study examines the existence of chronically
HIV-1-infected patients who harbor viral isolates with a hy-
persusceptible phenotype to multiple protease inhibitors along
with a low in vitro replication capacity.
MATERIALS AND METHODS
Study population and specimens. The samples analyzed were obtained during
a structured treatment interruption study conducted at the Hospital Universitari
Germans Trias i Pujol, Badalona, Spain. Full details of the selection criteria and
antiretroviral treatments are given elsewhere (28, 29). In brief, 12 HIV-1-in-
fected patients who had CD4 cell counts 600 cells/l and a CD4/CD8 ratio of
1 sustained for a minimum of 6 months and who had plasma HIV-1 RNA levels
below 50 copies/ml for at least 2 years before study entry were scheduled to
interrupt their antiviral therapy in an intermittent manner. These criteria were
chosen in order to enroll patients with well-conserved immunity and long-term
* Corresponding author. Mailing address: IrsiCaixa Foundation
Hospital Germans Trias i Pujol, Ctra. de Canyet, s/n 08916 Badalona,
Spain. Phone: 34 93 4656374. Fax: 34 93 4653968. E-mail: javiermp@ns
.hugtip.scs.es.
5907
viral suppression. Treatment interruptions during the first four cycles lasted for
a maximum of 30 days, or until plasma viral loads reached levels higher than
3,000 copies/ml in two consecutive determinations, after which highly active
antiretroviral treatment was resumed for approximately 90 days until the next
structured treatment interruption. In all cases, this resulted in suppression of
plasma viremia to less than 50 copies/ml prior to the next interruption. At the
fifth treatment interruption, patients remained off treatment for more than 12
months. Treatment regimens were fairly homogenous among patients and did
not include non-nucleoside reverse transcriptase inhibitors.
Viral sequence analysis. HIV-1 RNA isolated from patient plasma samples
was reverse transcription-PCR amplified and genotyped using population-based
sequencing for the protease and the reverse transcriptase at the peak of viremia
during each structured treatment interruption. Phylogenetic analyses of HIV-1
RNA sequences were performed to exclude cross-contamination. All samples
were determined to belong to subtype B.
Drug susceptibility assay. A rapid recombinant assay was used to measure the
drug susceptibility of the patients’ viral isolates (HIV PhenoSense, ViroLogic)
(24). This assay involves the construction of resistance test vectors, which are
comprised of a pool of recombinant HIV-1 containing gag (3 end from p7),
protease, and reverse transcriptase sequences derived from the virus sample that
is being evaluated. Resistance test vectors also contain a luciferase reporter gene
replacing env to monitor a single round of virus replication. Susceptibility of re-
sistance test vectors to a panel of antiretroviral drugs was compared to a refer-
ence vector containing the protease and reverse transcriptase sequences derived
from HIV-1NL4-3. Two independent measurements of each viral isolate were
obtained.
Replication capacity assay. Replication capacity was measured using a mod-
ified version of the PhenoSense drug susceptibility assay (6, 10). The relative
replication capacity of the virus was determined by measuring the amount of
luciferase activity produced 72 h after infection in the absence of drug. Repli-
cation capacity is expressed as the percentage of the luciferase activity produced
by the vectors containing patient-derived gag-pol sequences compared to the
luciferase activity from vectors containing the HIV-1NL4-3 gag-pol reference
sequences (100%). Replication capacity measurements were normalized for dif-
ferences in transfection efficiencies by monitoring the luciferase activity gener-
ated in transfected cells. Two replicates were performed for each sample.
Association between viral growth rate, CD4, CD8, and replication capacity.
Viral growth rates based on plasma viral load doubling time, CD4 and CD8
T-cell counts, and CD4/CD8 ratio during each structured treatment interruption
cycle had been previously calculated for the four first interruptions in the study
(9) and have been compared here with the replication capacity of each patient
isolate at each interruption.
Genetic basis of hypersusceptibility. Decision tree models describing the ge-
netic basis for hypersusceptibility to protease inhibitors in primary HIV-1 strains
were applied to our samples as previously described (15). The number of samples
defined as hypersusceptible with or without mutations at each position were also
compared using Fisher’s exact test (23).
Statistical analysis. Statistical analyses were performed using the R language
(http://www.r-project.org) and the GraphPad Prism version 4 (GraphPad Soft-
ware, San Diego, CA). The correlation analysis of susceptibility among different
protease inhibitors and also between protease inhibitor susceptibility and repli-
cation capacity was estimated using Spearmans rank correlation test. All P val-
ues were two-tailed.
RESULTS
Protease inhibitor susceptibility and genotype. The drug
susceptibility and pol sequences of 61 viral isolates derived
from 12 patients were evaluated. For lopinavir, only 53 viral
isolates were included in the analysis. The median change in
the 50% inhibitory concentration for the different protease
inhibitors ranged from 0.5-fold for amprenavir to 0.8-fold for
nelfinavir, with nelfinavir being the only drug with a 75% per-
centile slightly higher than 1 (Fig. 1A). Although the median
protease inhibitor change (except nelfinavir) previously re-
ported for HIV-1 lacking any drug-selected mutations is also
less than 1-fold (22), the values determined here were even
lower than this. Using a definition of hypersusceptibility of a
change 0.4-fold or lower, 23 (38%) isolates were hypersuscep-
tible to amprenavir, 21 (34%) to ritonavir, 11 (18%) to indi-
navir, 9 (17%) to lopinavir, 12 (20%) to saquinavir, and 7
(11%) to nelfinavir. Ten out of 12 patients had at least one
sample hypersusceptible to 1 protease inhibitor. The median
change in protease inhibitor susceptibility for each patient
ranged from 0.3-fold for patient 3 to 0.9-fold for patient 12
(Fig. 1B).
We also compared the median susceptibility values for drugs
in each of the three antiretroviral classes for which we had
data. Susceptibility to protease inhibitors (median  0.60) was
significantly lower than susceptibility to nucleoside reverse
transcriptase inhibitors (median  0.84, P  0.0001, Wilcoxon
matched-pair test) and non-nucleoside reverse transcriptase
FIG. 1. Box-plot representation of phenotypic susceptibility to protease inhibitors. (A) Values for all patients grouped by protease inhibitor.
A total of 61 determinations were performed for each protease inhibitor except for lopinavir, which had 53. (B) Values for all protease inhibitors
grouped by patient. Five to six determinations were obtained for each patient except for patient 9, who had only two because plasma viral load
did not rebound after some of the treatment discontinuations. For each box, the center line represents the median change, the box boundaries
define the 25th and 75th percentiles, and the whiskers define the 10th and 90th percentiles. Change values are relative to HIV-1NL4-3. APV,
amprenavir; IDV, indinavir; LPV, lopinavir; NFV, nelfinavir; RTV, ritonavir; SQV, saquinavir.
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inhibitors (median  1.13, P  0.0001). Therefore, the hyper-
susceptibility phenomenon is confined to the protease inhibitor
class.
None of the patient isolates contained primary protease in-
hibitor-associated mutations (mutations 24, 30, 32, 46, 47, 48,
50, 54, 82, 84, 88, and 90) over the course of the study, in agree-
ment with phenotypic data: no viral isolate had a fold change
value above the PhenoSense assay biological cutoff (22).
Low replication capacity. The median replication capacity
for all of the patient isolates was 57.6% (mean, 53.1%), with 25
and 75% percentiles of 29.7 and 72.0%, respectively. Patients
whose samples had the lowest replication capacity (patients 2,
3, and 10) were the same than those with the lowest protease
inhibitor change. Median replication capacity for all patients
grouped by number of structured treatment interruptions
ranged from 41 to 63% (Fig. 2A); the median of all values
grouped by patient ranged from 13 to 74% (Fig. 2B). No
significant changes in replication capacity were observed over
the course of repetitive interruptions.
Correlation between protease inhibitor susceptibility and
replication capacity. Correlation analysis of log-transformed
drug susceptibility and replication capacity values were signif-
icantly positive for all protease inhibitors tested. Amprenavir
showed the highest correlation with replication capacity ( 
0.65, P  0.0001), while lopinavir susceptibility had the lowest
correlation (  0.44, P  0.0011). However, the relationship
was better fitted by the quadratic curves shown in Fig. 3 than
by straight lines, with the exception of saquinavir, for which
there was no significant difference between the models.
Correlation between protease inhibitor susceptibilities. Pair-
wise protease inhibitor susceptibility analysis showed high cor-
relation values among all pairs of protease inhibitors tested
(Table 1). Amprenavir and ritonavir had the highest correla-
tion (  0.92, P  0.0001), while indinavir and lopinavir had
the lowest (  0.66, P  0.0001).
Correlation between replication capacity and growth rate
during structured treatment interruptions. Plasma viral load
doubling times during each structured treatment interruption
did not correlate with replication capacity (Fig. 4), and neither
did absolute CD4 or CD8 cell counts or the CD4/CD8
ratio.
Genotypic predictors of hypersusceptibility. Decision tree
models previously built to analyze the genotypic predictors of
hypersusceptibility to ritonavir in viral strains isolated from
patients with primary infection (15) did not predict hypersus-
ceptibility in the viral isolates used in this study. Individual
mutations positively associated with hypersusceptibility to all
protease inhibitors tested were R41K and I93L, with the ex-
ception of I93L to nelfinavir. Mutations negatively associated
with protease inhibitor hypersusceptibility (i.e., the mutation is
less prevalent in hypersusceptible samples) were L10V, I13V,
and L19P/I for amprenavir; I64L/V for indinavir; and T12P/S/I,
I13V, L19P/I, and I64L/V for ritonavir.
DISCUSSION
The present study describes the existence of viral isolates
that are hypersusceptible to multiple protease inhibitors and
have low replication capacity in patients with chronic HIV-1
infection. The cohort presented here was selected based on
preservation of CD4 cells and excellent response to highly
active antiretroviral treatment to perform studies of structured
treatment interruption (8, 9, 25, 28, 29). The drug susceptibility
and replication capacity study was done retrospectively without
excluding any patient, and therefore hypersusceptibility to pro-
tease inhibitors and low replication capacity were not expected
in advance.
Hypersusceptibility to specific protease inhibitors has previ-
ously been associated with single mutations that confer resis-
tance to other drugs. In particular, HIV-1 bearing an artificially
introduced substitution, V82T, in protease showed increased
susceptibility to saquinavir (19), although this has not yet been
confirmed in clinical isolates. N88S, a mutation that confers
resistance to nelfinavir, has been shown to cause hypersuscep-
tibility to amprenavir in both laboratory viruses and clinical
isolates (26, 35). Hypersusceptibility to ritonavir has recently
FIG. 2. Box-plot representation of the replication capacity values measured as a percentage of the patient’s virus with respect to the reference
HIV-1NL4-3 (100%). (A) Values grouped by pretreatment determination (PreTx) and peak of viremia at each structured treatment interruption.
Nine to 11 values are included per time point. (B) Values grouped by patient. Five to six determinations were obtained for each patient except
for patient 9, who had only two because plasma viral load did not rebound after some of the treatment discontinuations.
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been described in up to 12% of 182 cases of untreated primary
infected patients (15).
Here we extend the observation to protease inhibitor hyper-
susceptibility in isolates from chronically HIV-1-infected pa-
tients who do not show specific protease inhibitor resistance-
associated mutations. Interestingly, increased susceptibility in
this cohort was common to all protease inhibitors tested, with
10 out of 12 patients having at least one sample being hyper-
susceptible to at least one protease inhibitor. Therefore, the
overall increases in drug susceptibility in the study cohort can-
not be assigned to specific patients. Moreover, the median
drug susceptibility for the six protease inhibitors tested was
0.2-fold lower than the median drug susceptibility of almost
3,000 wild-type viruses from the ViroLogic database (22), in-
dicating that intrinsic virus characteristics are responsible for
the hypersusceptible phenotype.
The hypersusceptibility phenomenon in the present cohort
FIG. 3. Relationship between susceptibility to protease inhibitors and replication capacity. A total of 61 determinations were performed for
each protease inhibitor except for lopinavir, which had 53. R2 indicates the percentage of variability of the independent variable explained by the
dependent variable.
FIG. 4. Correlation between replication capacity and plasma vire-
mia doubling time during therapy discontinuations. The analysis in-
cluded a total of 61 determinations.
TABLE 1. Pairwise correlations of susceptibility changea
Protease inhibitor comparison  P
Amprenavir vs. indinavir 0.78 0.0001
Amprenavir vs. lopinavir 0.89 0.0001
Amprenavir vs. nelfinavir 0.79 0.0001
Amprenavir vs. ritonavir 0.92 0.0001
Amprenavir vs. saquinavir 0.82 0.0001
Indinavir vs. lopinavir 0.66 0.0001
Indinavir vs. nelfinavir 0.84 0.0001
Indinavir vs. ritonavir 0.84 0.0001
Indinavir vs. saquinavir 0.82 0.0001
Lopinavir vs. nelfinavir 0.67 0.0001
Lopinavir vs. ritonavir 0.85 0.0001
Lopinavir vs. saquinavir 0.81 0.0001
Nelfinavir vs. ritonavir 0.90 0.0001
Nelfinavir vs. saquinavir 0.78 0.0001
Ritonavir vs. saquinavir 0.84 0.0001
a A total of 61 determinations were performed for each inhibitor except lopi-
navir, which had 53.
5910 MARTINEZ-PICADO ET AL. J. VIROL.
has only been observed for protease inhibitors but not for
nucleoside reverse transcriptase inhibitor and non-nucleoside
reverse transcriptase inhibitors, suggesting that technical arti-
facts that lead to such results are unlikely. In addition, the
mean replication capacity of recombinant viruses containing
the 3 end of gag, the protease, and the reverse transcriptase
coding regions of all these isolates was only 53.1% (median,
57.6%), significantly lower than the expected average for wild-
type viruses (100%).
The strong correlation found among susceptibility values for
all the protease inhibitors tested is striking. The correlation
between protease inhibitor susceptibility and replication ca-
pacity was also remarkable. The Spearman correlation coeffi-
cient for ritonavir was 0.6 (P  0.0001), similar to the 0.5
observed for primary HIV strains (15). Correlation analyses at
the peak of viremia for the first, second, and third structured
treatment interruption separately retained statistical signifi-
cance (data not shown). In a large group of clinical samples
lacking protease inhibitor resistance mutations, there was a
significant correlation between replication capacity and pro-
tease inhibitor susceptibility (21). However, about 12% of the
samples in that study had either protease inhibitor hypersus-
ceptibility without low replication capacity or did not have
protease inhibitor hypersusceptibility in spite of having low
replication capacity, indicating that replication capacity might
not be the only determinant of protease inhibitor hypersuscep-
tibility (21).
It seems unlikely that the structured treatment interruption
had a direct effect on replication capacity, since the replication
capacity values did not change significantly over time. In fact,
pretreatment replication capacity values, when available, were
not different from those at the last structured treatment inter-
ruption. This would reflect that hypersusceptibility and low
replication capacity in this patient cohort are biological char-
acteristics linked to the patients rather than to the treatment
strategy. Of note, based on protease, reverse transcriptase, and
env genotypes, all viruses were subtype B (data not shown).
Eleven patients had R5 tropic viruses, and patient 8 harbored
dual tropic viruses (17); patients 5, 6, 8, and 9 were heterozy-
gous for CCR532 (17). None of these characteristics could be
directly associated with hypersusceptibility or low replication
capacity. However, it is plausible that the selection of the
studied cohort, based on high and sustained CD4 T-cell
counts, among other characteristics (25), might reflect reduced
viral pathogenesis, which in turn has been associated with
reduced replication capacity (11).
Of note, CD4 and CD8 T-cell counts and the CD4/CD8
ratios at the peak of viremia of each structured treatment
interruption could not be correlated with the replication ca-
pacity values. In turn, the good response to highly active anti-
retroviral treatment in these patients might be due to the
increased drug-susceptible phenotype of the viral variants an-
alyzed. Although the data shown here are restricted to samples
from the cohort described, other samples from chronically
HIV-infected patients also showed hypersusceptibility to pro-
tease inhibitors as well as low replication capacity values in the
absence of protease inhibitor-associated mutations. For exam-
ple, a patient isolate with drug susceptibility change values of
0.35-fold to all protease inhibitors tested and a replication
capacity of 2% was recently observed (data not shown).
The genotypic basis of hypersusceptibility to protease inhib-
itors was explored by using the decision tree models built for
ritonavir hypersusceptibility in primary HIV strains (15). How-
ever, such models could not predict any combination of amino
acids at polymorphic sites or reduced replication capacity. This
result might indicate that the genotypic basis of hypersuscep-
tibility to protease inhibitor is different in primary and chronic
infection. Alternatively, it could suggest that such genotypic
determinants are so variable that they would change among
study groups (23). Although our analysis was based on pro-
tease alone, the inclusion of the 3-end gag region in the data
did not improve the performance of the model in primary HIV
strains (15). A recent report suggests that reduced replication
capacity in a wild-type population of HIV-1 could be explained
in part by mutations in p6 gag that occur at specific sites that
serve critical roles in binding to cellular proteins required for
viral budding (1). Of note, one of the gag mutations that were
significantly associated with low replication capacity values
(position 483, at the LYP motif that binds to AIP1) was also
included among the genotypic determinants of hypersuscepti-
bility to protease inhibitors and low replication capacity of
HIV-1 strains in primary infection (1, 15).
Since different patients’ samples had different in vitro rep-
lication capacity values, we intended to correlate them with in
vivo growth rates during structured treatment interruptions.
However, no correlation was found, most likely because the
effects of other genes such as env probably dwarf the variation
in replication capacity due to pol.
The clinical benefit of the hypersusceptibility phenomenon
when using protease inhibitor-based therapies has not been
investigated thoroughly. One preliminary study reported an
association between increased susceptibility to amprenavir and
response to amprenavir-containing regimens (30). Two pa-
tients of our cohort who were treated with lamivudine, stavu-
dine, and indinavir developed the M184V mutation in reverse
transcriptase after the second treatment interruption. Never-
theless, their plasma viremia returned to undetectable levels
after restarting the same therapeutic regimen, even when the
virus was phenotypically resistant to lamivudine (18). In both
cases, the rebounding virus containing the M184V mutation
was hypersusceptible to all protease inhibitors tested. We spec-
ulate that hypersusceptibility to indinavir could have been re-
sponsible for the virologic response in these patients.
This analysis is limited to a subset of viruses derived from a
small number of selected subjects. However, virus isolates from
the same patients showed consistently enhanced susceptibility
to the protease inhibitors tested. Unfortunately, the prevalence
and the identification of the viral characteristics linked to hy-
persusceptibility to protease inhibitors in patient-derived vi-
ruses are not straightforward. In contrast to hypersusceptibility
to non-nucleoside reverse transcriptase inhibitors, hypersus-
ceptibility to multiple protease inhibitors is not necessarily
associated with prior antiretroviral treatment.
In summary, hypersusceptibility to multiple protease inhib-
itors as well as low replication capacity can be found in recom-
binant viruses derived from chronically infected patients. How-
ever, the genetic basis of these phenomena remains elusive. A
treatment strategy based on repetitive controlled treatment
interruptions did not change the phenotype and replication
capacity values and did not correlate with virus growth rates
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after treatment discontinuation. The underlying mechanism of
protease inhibitor hypersusceptibility is unknown. It has been
proposed that variation in protease function is directly respon-
sible for variations in fitness among strains in primary HIV
infection (15). However, the impact of protease inhibitor hy-
persusceptibility on virologic response to protease inhibitor-
based therapies remains to be investigated.
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